Inhibitory effect of olopatadine hydrochloride (KW-4679), a novel antiallergic drug, on peptide leukotriene release from human eosinophils

Kiyomi Miyake, Kenji Ohmori, Akio Ishii, Akira Karasawa

Allergology International · 2001 · 13 citations · 12 references

DOIFull text

Open access

Concepts

Abstract

Olopatadine hydrochloride (olopatadine; KW-4679), (Z)-11-[(3-dimethylamino)propylidene]-6,11-dihydro-dibenz[b,e]oxepin-2-acetic acid monohydrochloride, is an antiallergic drug with selective and potent histamine H1 receptor antagonist activity. In the present study, we investigated the effect of olopatadine on the release of peptide leukotrienes (P-LT), potent inflammatory mediators, from human eosinophils. Human eosinophils were purified from venous blood of healthy donors by negative selection using the anti-CD16 antibody. When human eosinophils were stimulated with the calcium ionophore A23187 (1 μmol/L), the amount of P-LT release was approximately 1200 pg/ 105 cells, while thromboxane (TX) B2 release was under the detection limit (< 20 pg/105 cells). Olopatadine inhibited the A23187-induced P-LT release from human eosinophils with an IC50 of 4.5 μmol/L. Ketotifen also inhibited this reaction with an IC50 of 39.4 μmol/L. The inhibitory effect of olopatadine on the P-LT release may contribute to the antiallergic efficacy of this drug.

References

12